Cytokinetics, Incorporated (CYTK) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for Cytokinetics, Incorporated, with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| P/E Ratio | -9.72x | -8.94x | -15.31x | -10.58x | -16.28x | -10.53x |
| P/B Ratio | -11.56x | -38.91x | -20.86x | -38.14x | 14.37x | 11.83x |
| P/S Ratio | 86.62x | 285.13x | 1070.22x | 43.51x | 49.76x | 24.02x |
| Profitability | ||||||
| Gross Margin | 88.5% | -1737.2% | -4284.1% | -154.6% | -127.1% | -73.7% |
| Operating Margin | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% | -168.3% |
| Net Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | -228.0% |
| EBITDA Margin | -880.6% | -2671.2% | -6064.9% | -348.2% | -250.4% | -155.4% |
| Liquidity | ||||||
| Current Ratio | 4.53x | 6.17x | 6.12x | 9.40x | 7.45x | 15.20x |
| Quick Ratio | 4.53x | 6.17x | 6.12x | 9.40x | 7.45x | 15.20x |
| Leverage | ||||||
| Debt/Equity | -1.95x | -5.83x | -1.96x | -6.95x | 1.11x | 1.23x |
YoY = year-over-year change. Source: FMP..